Podcasts about conference coverage

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Bruno Batinica, MD Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performance across diverse health systems, the potential value of combining modalities to improve positive predictive value, and next steps toward prospective deployment in clinical practice.

Guest: Bruno Batinica, MD Earlier recognition of ATTR-CM remains a challenge, but emerging applications of AI could offer a new way to raise clinical suspicion. Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, explores how AI models could identify patterns in ECG and echocardiography that may help flag patients for further evaluation.

Guest: Noel Bairey Merz, MD Cardiovascular risk in women can emerge well before older age, but traditional approaches to risk assessment may overlook sex-specific factors in patients under 65. Dr. Noel Bairey Merz joins us to share how tools such as the PREVENT score and coronary artery calcium scoring, along with obstetric history and female-dominant conditions, can help us identify elevated risk earlier. Dr. Bairey Merz is the Director of the Barbra Streisand Women's Health Center, the Linda Joy Pollin Women's Heart Health Program, and the Preventive and Rehabilitative Cardiac Center at the Cedars-Sinai Smidt Heart Institute in Beverly Hills, California. She also spoke about this topic at the 2026 European Society of Cardiology Congress.

In this podcast, featuring audio from a live webinar, experts Claudia P. Cortes, MD, and Chloe Orkin, MBChB, FRCP, MD, explore advancements in HIV prevention and treatment presented at the 26th International AIDS Conference (AIDS 2026). To download the accompanying slides and view more conference coverage, visit the program page. Topics covered include: New clinical trial and real-world data for available and emerging initial antiretroviral therapy (ART) regimens for people living with HIV Long-acting options for ART and HIV pre-exposure prophylaxis (PrEP). Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters:Claudia P. Cortes, MD Full Professor Director for Centre for HIV AIDS Integral Research – CHAIR Universidad De Chile Santiago, Chile Chloe Orkin, MBChB, FRCP, MD Professor of Infection and Inequities Dean for Healthcare Transformation Faculty of Medicine and Dentistry Queen Mary University of London Honorary Consultant Physician, Barts Health NHS Trust London, United Kingdom Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Scott D. Isaacs, MD FACP, FACE For patients with diabetes, effective care requires more than just lowering A1C. Dr. Scott Isaacs joins us to discuss the importance of incorporating comorbidities into care and strategies for systematic screening and follow-up. He's the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of Medicine at Emory University School of Medicine.

Guest: Scott D. Isaacs, MD FACP, FACE For patients with type 2 diabetes, the latest American Association of Clinical Endocrinology (AACE) guidance supports tailoring hypertension treatment to individual risk profiles. Dr. Scott Isaacs joins us to review updated blood pressure targets, first-line therapies, and management considerations for patients at increased risk. He's the Immediate Past President of the AACE and an Associate Professor of Medicine at Emory University School of Medicine.

Host: Marshall Miller Guest: Ami R. Patel From fracture liaison services to menopause care, the 2026 Interdisciplinary Symposium on Osteoporosis (ISO) covered the latest advances and interdisciplinary strategies in bone health. Join Marshall Miller and Ami Patel, Vice President of Science and Education at the Bone Health and Osteoporosis Foundation, for a recap of this year's meeting.

Guest: Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.

Guest: John W. Ostrominski, MD, MPH Despite advances in glycemic management, blood pressure control, lipid lowering, and disease-modifying therapies, patients with chronic kidney disease (CKD) and type 2 diabetes continue to face substantial residual cardiovascular risk. In this program, Dr. John Ostrominski reviews emerging evidence linking low-grade systemic inflammation to adverse cardiovascular outcomes in this high-risk population, highlighting findings from the FIDELITY pooled analysis of FIDELIO-DKD and FIGARO-DKD. Dr. Ostrominski is a fellow specializing in cardiovascular disease and obesity medicine at Brigham and Women's Hospital and Harvard Medical School. He spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Guest: Kimberly Narain, MD, MPH, PhD Cost-related medication nonadherence remains a significant but often hidden barrier to effective diabetes care, with out-of-pocket costs preventing patients from accessing essential therapies. Dr. Kimberly Narain joins us to explain why clinicians should look beyond insurance status alone and consider affordability challenges when developing strategies to improve diabetes outcomes. Dr. Narain is an Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, as well as the Director of Health Services and Health Optimization Research at the Iris Cantor UCLA Women's Health Center. She also spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Guest: Jaime Imitola, MD As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments, investigational approaches, and unproven interventions marketed through stem cell tourism. Hear more as Dr. Jaime Imitola discusses the current landscape of stem cell therapies in MS, the risks associated with unregulated treatments, and the importance of patient education and evidence-based guidance. Dr. Imitola is the Vice Chair for Research of the Department of Neurology and the Director of the Division of Multiple Sclerosis and Translational Neuroimmunology at UConn Health. He also spoke about this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Host: Steve Jackson, PharmD Guest: Souptik Barua, PhD Guest: Emily Johnston, MPH, PhD Can older adults successfully engage with telehealth, wearable technology, and digital health tools to prevent type 2 diabetes? In this conversation with Dr. Steve Jackson, Ds. Emily Johnston and Dr. Souptik Barua discuss emerging insights on how these strategies could improve accessibility and engagement in a high-risk population. Dr. Johnston is a Research Assistant Professor in the Department of Medicine, and Dr. Barua is an Assistant Professor in the Division of Precision Medicine at the NYU Grossman School of Medicine. They presented these findings at the 2026 American Diabetes Association Scientific Sessions.

Guest: Jaime Imitola, MD As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments, investigational approaches, and unproven interventions marketed through stem cell tourism. Hear more as Dr. Jaime Imitola discusses the current landscape of stem cell therapies in MS, the risks associated with unregulated treatments, and the importance of patient education and evidence-based guidance. Dr. Imitola is the Vice Chair for Research of the Department of Neurology and the Director of the Division of Multiple Sclerosis and Translational Neuroimmunology at UConn Health. He also spoke about this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: Javier Morales, MD, FACP, FACE For patients with obesity and type 2 diabetes (T2D), emerging incretin-based therapies that target multiple metabolic pathways are producing meaningful weight-loss outcomes. To learn more about these care strategies, tune in as Dr. Javier Morales shares key updates from the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Guest: Javier Morales, MD, FACP, FACE From proactive screening to once-weekly insulin, the treatment landscape for type 1 diabetes is evolving rapidly. Join Dr. Javier Morales to hear about current and emerging care strategies in these patients, a topic he also discussed at the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Guest: Elizabeth S. Gromisch, PhD Cognitive changes are a common but complex aspect of multiple sclerosis care, making practical and accessible screening strategies essential. In this program, Dr. Elizabeth Gromisch explores both traditional and digital cognitive screening tools for MS and shares real-world insights on selecting and implementing assessments across a range of clinical settings. Dr. Gromisch is a research neuropsychologist at the Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience Research at Mount Sinai Rehabilitation Hospital, Trinity Health of New England. She also discussed this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: Elizabeth S. Gromisch, PhD Cognitive changes are a common but complex aspect of multiple sclerosis care, making practical and accessible screening strategies essential. In this program, Dr. Elizabeth Gromisch explores both traditional and digital cognitive screening tools for MS and shares real-world insights on selecting and implementing assessments across a range of clinical settings. Dr. Gromisch is a research neuropsychologist at the Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience Research at Mount Sinai Rehabilitation Hospital, Trinity Health of New England. She also discussed this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: Abdallah Geara, MD IgA nephropathy is often asymptomatic and frequently identified through incidental lab findings, making timely recognition challenging. Hear Dr. Abdallah Geara discuss key diagnostic strategies that may help optimize long-term care for this disease. Dr. Geara is an Associate Professor of Clinical Medicine and the Clinical Director of the Glomerular Disease Program at the Perelman School of Medicine at the University of Pennsylvania, and he spoke at the 2026 National Kidney Foundation Spring Clinical Meeting.

Guest: Abdallah Geara, MD Early diagnosis is critical in IgA nephropathy, as most patients present with established kidney damage by the time they are identified. Tune in to hear Dr. Abdallah Geara highlight the importance of timely recognition and how emerging therapies are transforming treatment and improving patient outcomes when implemented early.

Guest: Deborah Clegg, PhD Not all potassium is created equal, especially in the context of chronic kidney disease (CKD). That's why Dr. Deborah Clegg joins us to explore the key differences between potassium from whole foods and additives, emphasizing how bioavailability impacts serum potassium levels and hyperkalemia risk. She also examines how kidney function, comorbidities, medications, and metabolic factors all influence potassium tolerance. Not only is Dr. Clegg the Vice President for Research and a Professor in the Department of Internal Medicine at Texas Tech University Health Sciences Center in El Paso, but she also spoke about this topic at the 2026 National Kidney Foundation Spring Clinical Meeting.

Presenter: Louis Bessette MD, FRCP(C), MSc What can nearly two decades of real-world data teach us about optimizing care in early inflammatory arthritis? Find out with Dr. Louis Bessette as he reviews key findings from the Canadian Early Arthritis Cohort (CATCH), a national, multicenter study of nearly 4,000 patients enrolled within weeks of symptom onset. Not only is Dr. Bessette a Professor of Medicine at Université Laval and the Director of the Centre for Osteoporosis and Rheumatology of Québec, but he also spoke about this topic at the 2026 Congress of Clinical Rheumatology East conference.

Guest: Avery H. LaChance, MD, MPH, FAAD Cutaneous dermatomyositis has a distinct pattern of skin findings that, once recognized, can make diagnosis much more straightforward. Tune in to hear Dr. Avery H. LaChance walk through the key visual clues and exam tips that help bring this condition into focus. Dr. LaChance is Director of the Connective Tissue Disease Clinic, Director of the Advanced Psoriasis Therapeutics Clinic, Director of Health Policy and Advocacy, and Program Director of the Dermatology-Rheumatology Fellowship at Brigham and Women's Hospital. She's also an Associate Professor of Dermatology at Harvard Medical School, and she spoke on this topic at the 2026 Congress of Clinical Rheumatology East.

Guest: Avery H. LaChance, MD, MPH, FAAD Acute and subacute cutaneous lupus each have recognizable skin presentations that can help guide diagnosis, especially when distinguishing them from similar conditions. Join Dr. Avery H. LaChance as she breaks down their key diagnostic features, common mimics, and important considerations for clinical evaluation. Dr. LaChance is Director of the Connective Tissue Disease Clinic, Director of the Advanced Psoriasis Therapeutics Clinic, Director of Health Policy and Advocacy, and Program Director of the Dermatology-Rheumatology Fellowship at Brigham and Women's Hospital. She's also an Associate Professor of Dermatology at Harvard Medical School, and she spoke on this topic at the 2026 Congress of Clinical Rheumatology East.

Presenter: Louis Bessette MD, FRCP(C), MSc From early arthritis treatment pathways to emerging digital health tools, the 2026 Congress of Clinical Rheumatology East conference spotlights the clinical and scientific advances shaping the future of rheumatology care. Joining us to outline those key themes and sessions is Dr. Louis Bessette, Professor of Medicine at Université Laval and the Director of the Centre for Osteoporosis and Rheumatology of Québec.

Guest: Jeanette Andrade, PhD, RDN, LDN, FAND Food and nutrition insecurity are increasingly recognized as critical factors affecting outcomes for patients with chronic kidney disease (CKD). That's why Dr. Jeanette Andrade joins us to share practical screening strategies and emerging solutions, like dialysis center food pantries and digital health tools. Dr. Andrade is an Associate Professor and the Director of the Master's in Dietetic Internship Program at the University of Florida, and she spoke about this topic at the 2026 National Kidney Foundation Spring Clinical Meeting.

Guest: Deborah Clegg, PhD For decades, potassium restriction has been a cornerstone of dietary management in patients with chronic kidney disease (CKD), but is it always necessary? Here to answer that exact question is Dr. Deborah Clegg. Since many patients may already be consuming potassium at restricted levels, she emphasizes the importance of individualized dietary assessment before imposing further limitations. Dr. Clegg is the Vice President for Research and a Professor in the Department of Internal Medicine at Texas Tech University Health Sciences Center in El Paso.

Guest: Jeanette Andrade, PhD, RDN, LDN, FAND Food and nutrition insecurity in chronic kidney disease (CKD) can be difficult to detect, even when patients appear clinically stable. To help highlight this challenge, Dr. Jeanette Andrade presents a case from her research illustrating how social and financial stressors affected a dialysis patient's dietary intake and food access. Dr. Andrade is an Associate Professor and the Director of the Master's in Dietetic Internship Program at the University of Florida, and this patient case was part of her presentation at the 2026 National Kidney Foundation Spring Clinical Meeting.

Host: Matt Birnholz, MD Guest: Abigail Sporer, PhD, MBA At the intersection of expertise, strategy, and collaboration, medical affairs professionals are translating vaccine science into meaningful and actionable insights for healthcare providers. In this candid conversation from the 2026 Medical Affairs Professional Society (MAPS) Annual Meeting, Dr. Matt Birnholz and Dr. Abigail Sporer, Director of US Medical Affairs at CSL Seqirus, discuss the evolving realities of vaccine education, from addressing misinformation to strengthening engagement. Learn more about how medical affairs plays a role in supporting clinicians and improving communication in a complex public health landscape.

Host: Matt Birnholz, MD Guest: Karen Roy, MSc For medical affairs teams, demonstrating the value and impact of educational initiatives in a meaningful and measurable way is essential. At the 2026 Medical Affairs Professional Society (MAPS) Annual Meeting, Dr. Matt Birnholz spoke with Ms. Karen Roy, CEO and Co-Founder of Infograph-ed, about how CME-informed strategies can elevate planning, content design, and outcomes measurement. Learn more about new approaches that can help create more targeted, insight-driven education.

Tune into this podcast, featuring audio from a live conference coverage webinar, to learn from global experts, Monica Gandhi, MD, MPH, and Jean-Michel Molina, MD, as they summarize and discuss the latest updates on HIV treatment and prevention from CROI 2026. Topics covered include: Emerging HIV treatments Advances in HIV prevention Investigational agents for HIV prevention Early-phase investigational HIV treatments For more coverage of CROI 2026, and to follow along with the downloadable slides, visit the program page:https://bit.ly/4bmS062 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Monica Gandhi, MD, MPH Professor of Medicine and Associate Chief Division of HIV, Infectious Diseases, and Global Medicine Director, UCSF Center for AIDS Research (CFAR) Director of HIV Special Program "Ward 86" HIV Clinic San Francisco General Hospital San Francisco, California Jean-Michel Molina, MD Professor of Medicine Saint-Louis and Lariboisire Hospitals Université Paris Cité Paris, France   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,  about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium. Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Virginia Kaklamani, MD, DSc Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Link to full program:https://bit.ly/46Qv9OK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Congress, which investigated neoadjuvant immune checkpoint blockade in mismatch-repair-proficient (MMR-p) colon cancer. In addition to confirming that combination immunotherapy prior to surgery is a safe and feasible approach, the study also found that circulating tumor DNA (ctDNA) levels correlated with both tumor burden and early treatment response. Joining Dr. Brian McDonough to unpack these insights is Dr. Christopher Chen, Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

Guest: John H. Strickler, MD The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomes in this complex disease setting. Dr. Strickler is a Professor of Medicine in the Division of Medical Oncology at Duke University School of Medicine and Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute.

Guest: Daniela Molena, MD For patients with locally advanced gastroesophageal cancer, surgery remains a critical component of curative treatment—even in the era of chemoradiation and advanced imaging. Dr. Daniela Molena explores the challenges of assessing complete clinical response and the risks of non-operative management. Dr. Molena is an Associate Professor of Surgery at Weill Cornell Medicine and a Thoracic Surgeon at Memorial Sloan Kettering Cancer Center, and she discussed this topic at the 2026 ASCO Gastrointestinal Cancers Symposium.

Guest: William Hall, MD From tumor detection to biomarker development, artificial intelligence (AI) is rapidly reshaping the landscape of gastrointestinal oncology. In this expert-led program, Dr. William Hall explains how AI is being applied to data to identify tumor features and treatment susceptibilities faster and more precisely than traditional methods. Dr. Hall is a Professor and Chair of Radiation Oncology at the Medical College of Wisconsin, and he spoke about this topic at the 2026 ASCO Gastrointestinal Cancers Symposium.

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett Jones Distinguished ChairMD Anderson Cancer CenterHouston, TexasSolange Peters, MD, PhD Professor and Director of Medical OncologyDepartment of OncologyUniversity Hospital of LausanneLausanne, SwitzerlandContent based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.Link to full program: https://bit.ly/3L1eksIGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Seth Wander, MD, PhD Over the past decade, CDK4/6 inhibitors have transformed the treatment landscape for HR+ breast cancer, but resistance remains a key clinical challenge. Hear from Dr. Seth Wander as he explores the latest translational insights into resistance mechanisms, including genomic alterations affecting cell cycle and signal transduction pathways, and discusses evolving therapeutic strategies. Dr. Wander is an Assistant Professor of Medicine at Harvard Medical School and the Director of Precision Medicine at the Termeer Center for Targeted Therapies at Mass General Brigham Cancer Institute. He also spoke about this topic at the 2025 San Antonio Breast Cancer Symposium.

Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.

Tune into this podcast to revisit discussions led by global experts, Karine Lacombe, MD, PhD, and Chloe Orkin, MBChB, FRCP, MD, featuring the latest updates on HIV treatment and prevention from the 2025 IDWeek and EACS conferences.Topics covered include:Real-world safety and efficacy of long-acting ARTART switch: preferences, treatment satisfaction, changes in weight and metabolic parameters, and HBV reactivation riskInvestigational therapiesUpdates on long-acting PrEP: persistence, use in people with substance use disorder, and coadministration with gender-affirming hormone therapyHIV and STI screening with PrEPSTI prevention To download the accompanying slides, visit the program page for this episode:https://bit.ly/3MGvegMPresenters:Karine Lacombe, MD, PhDProfessor of MedicineSorbonne UniversityHead of Infectious Diseases UnitSt Antoine Hospital, AP-HPParis, FranceChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomGet access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Ryan Quigley Guest: Kathrin M. Bernt, MD Guest: Rushabh Mehta, BS Guest: Fatemeh Alikarami New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kathrin Bernt, Dr. Fatemah Alikarami, and Mr. Rushabh Mehta to discuss how their findings could impact minimal residual disease detection, therapy resistance, and future risk stratification strategies. Dr. Bernt is a pediatric oncologist and an Associate Professor of Pediatrics at the Children's Hospital of Philadelphia. Dr. Alikarami is a Research Associate Scientist at the Children's Hospital of Philadelphia. Mr. Mehta is a PhD candidate in cell and molecular biology at the University of Pennsylvania.

Thanks for listening, and please follow us on Insta @NHPTalent and www.youtube.com/thePOZcastFor all episodes, please check out www.thePOZcast.com CHAPTERS / TIMESTAMPS00:00 – Welcome to RecFest Nashville 2025Adam sets the scene and kicks off day two of #thePOZcast live from the Juicebox.ai booth.00:28 – Guest 1: Steve Levy – The Elder Statesman of Recruiting WisdomSteve shares why RecFest stands apart, how it fosters real community, and why curiosity—not automation—keeps recruiters sharp.02:45 – Learning, Listening, and the Power of CuriositySteve drops classic Levy gems: “Two ears, one mouth—use them proportionally.” A masterclass in humility and experimentation.05:18 – Advice for Job Seekers in a Tough MarketSteve explains why teaching others what you've learned and practicing gratitude are secret weapons for staying visible and relevant.06:57 – Final Word: CommunityThe legendary recruiter sums up RecFest 2025 in one word: Community.08:13 – Guest 2: Brian Petroski (EXP)Director of TA shares insights on recruiting engineers at scale, sourcing tools that work (LinkedIn, HireEZ, Indeed), and standing in line for Nashville's best food truck.10:37 – Guest 3: Leslie Harrah & Kim Johnson (Fortified Health Security)Two powerhouse women in cybersecurity recruiting talk about connecting with people, building culture, and the beauty of the TA community.12:01 – Pivoting Careers & Finding New OpportunitiesAdam shares tactical advice for job seekers on leveraging certifications, curiosity, and career pivots into hot sectors like cybersecurity and clean tech.12:59 – Guest 4: Taylor Hunter (Gaylor Electric)Insights on ATS tools, recruiting high-level talent, and how scraping extensions and sourcing hacks make life easier for busy TA pros.15:23 – Guest 5: Carmen Scanlon (Belong HQ)On startup life, meaningful networking, and the simplicity and depth that make RecFest so special.17:26 – Closing: Gratitude from the FieldAdam wraps from the food trucks with final reflections on connection, learning, and community. 

Thanks for listening, and please follow us on Insta @NHPTalent and www.youtube.com/thePOZcastFor all episodes, please check out www.thePOZcast.com  Chapter Breakdown00:00 – Welcome to RecFest Nashville 2025Adam sets the scene at the Juicebox.ai booth and kicks off #thePOZcast live from the field.00:28 – Guest 1: Omar Khateeb – The Power of Authentic Video ContentCEO of JobPixel on why “vibe is everything,” how authenticity wins in 2025, and why creators should stop chasing algorithms.02:24 – Survival Tips for RecFestHydrate, eat before noon, and network smarter — Omar's pro tips for surviving outdoor conferences.03:45 – Guest 2: Allyn Bailey – The Heart of Brand Experience at SmartRecruitersAlynn breaks down how storytelling and connection drive talent strategy post-acquisition — and why she proudly calls herself “the class mom” of HR tech.06:54 – Guest 3: Jamie Leonard – The RecFest Origin & Future VisionThe founder himself on why RecFest feels like summer camp for recruiters, the UK vs. US vibes, and what's next (spoiler: Ferris wheel?).10:50 – Guest 4: Vicky Lou – Inside Juicebox.ai's Series A RocketshipThe founding marketer shares what makes Juicebox's AI sourcing platform different, how startup life fuels creativity, and her secret to building high-performing teams.14:49 – Sticker Drop & Shoutout to Juicebox.aiAdam and Vicky unveil the ultra-rare holographic POZcast sticker and talk sponsor love.16:11 – Guest Panel: Nikki Russell, Dan Lockhart & Chantelle LubingerReal-world TA leaders on quality of slate, giving rejection with empathy, and why “we're humans first.”21:44 – Guest 7: John Ruffini – Old School Recruiting Wisdom Meets New TechThe VP of Professional Development at HealthTrust Workforce Solutions explains why recruiters have gotten lazy, how to bring back urgency, and the lost art of the phone call.28:16 – The AI Debate & Juicebox Agents in ActionAdam and John discuss how to use AI as a tool — not a crutch — and how it frees recruiters for the human side of the job.29:09 – Closing Thoughts: Stay Human, Stay HungryAdam wraps from the field with gratitude, laughter, and the promise that wisdom is forever.

Hear from experts in HIV care Beatriz Grinsztejn, MD, PhD, and Rosie Mnggibisa, MBChB, MPH, as they discuss their insights on some of the most clinically relevant new data presented at IAS 2025, including studies on: Gaps in care for adolescents and young adults living with HIVGlobal impact of funding cutsAntiretroviral therapy for treating HIVPatient management strategies for people living with HIV and obesityPresenters:Beatriz Grinsztejn, MD, PhDDirectorSTI/HIV Clinical Research LaboratoryEvandro Chagas National Institute of Infectious Diseases – FIOCRUZRio de Janeiro, BrazilRosie Mngqibisa, MBChB, MPHClinical DirectorPrincipal InvestigatorEnhancing Care FoundationDurban, South AfricaLink to full program: https://bit.ly/4otF8AR

The Word of the Day is Perspective (0:00-37:58) Eagles owner Jeffery Lurie addresses the media during the NFL's annual League Meetings, where he will discuss topics such as the Tush Push, Dallas Goedert, and the upcoming Parade. (37:58-40:46) Tyrone expresses gratitude for strong ownership, particularly in light of Jerry Jones providing another noteworthy soundbite for the media. (40:46-46:24) Jones remarked that agents do not influence the game on the field, clarifying that he did not intend to offend the league's agents. He asserts that he and the players are the primary factors affecting on-field performance. Follow The Station x.com/975TheFanatic instagram.com/975thefanatic/ https://www.facebook.com/975thefanatic/ Follow The Show x.com/975BestShowEver https://x.com/TyJohnsonNews https://x.com/rickybottalico https://x.com/sylvanakell Support the Show 975thefanatic.com/shows/the-best-show-